Posttransplant HCV: meta-analysis fails to support add-on ribavirin

  • Xue W & al.
  • Int J Infect Dis
  • 5 Apr 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • A meta-analysis suggests limited utility for ribavirin (RBV) in patients receiving sofosbuvir (Sovaldi)-based direct-acting antiviral (DAA) regimens for HCV recurrence after liver transplant.

Why this matters

  • Findings have important implications in the context of HCV+ organ donation.

Key results

  • Pooled sustained virologic response at 12 weeks posttherapy (SVR12) rate, 91% (95% CI, 84%-95%), with high heterogeneity (I2=88%; P<.01 but no evidence of publication bias.>
  • SVR12 was similar in patients receiving and not receiving RBV (90% vs 94%; risk ratio [RR]=0.97; P=.35; I2=46%), regardless of:
    • Therapy duration of 12 vs 24 weeks (P=.26).
    • DAA targets (NS3/4A+NS5B vs NS5A+NS5B inhibitors; P=.76).  
    • Studies conducted in the U.S. vs Europe (P=.13). 
  • RBV inclusion was associated with an increased prevalence of anemia (42% vs 10%; RR=5.18; P<.00001 i>2=26%).

Study design

  • Meta-analysis of 12 studies involving 1466 liver transplant recipients receiving sofosbuvir-based DAA regimens with (n=502) and without RBV (n=964).
  • HCV-1 was predominant (81%); approximately 58% were treatment-experienced.
  • Primary endpoint: SVR12.
  • Funding: National Natural Science Foundation of China, National Science and Technology Major Project of China, Chongqing Natural Science Commission Foundation.

Limitations

  • Only 1 randomized controlled trial included.
  • No genotype-specific analysis.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit